Urologix, Inc. reported unaudited earnings results for the first quarter ended September 30, 2014. For the quarter, sales were $3,021,000 against $3,779,000 a year ago. The decreases in Revenues were driven by reduced sales of both CTT and Prostiva products. Operating loss was $241,000 against $1,162,000 a year ago. Loss before income taxes was $432,000 against $1,322,000 a year ago. Net loss was $437,000 against $1,334,000 a year ago. Net loss per common share--basic and diluted was $0.02,000 against $0.06,000 a year ago. Net cash used in operating activities was $170,000 against $734,000 a year ago. Purchases of property and equipment were $1,000 against $2,000 a year ago. Purchases of intellectual property were $2,000 against $3,000 a year ago.

For the fiscal 2015, the company expects positive cash flow from operations and support building upon the evidence demonstrating the cost-effectiveness of in-office BPH technologies. The company expected some lower sales volume in 2015 fiscal year with its new sales deployment model and organizational structure, but believes the restructuring has allowed to focus on a stronger base of business to first stabilize and then begin to expand upon.